Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Castor oil has sat on chemists’ shelves for centuries, first as a raw plant extract, then as the building block for more sophisticated materials. The use of polyoxyethylene (POE) castor oil didn’t spring up overnight. It grew from chasing solutions in drug formulation. Chemists started playing with ethoxylation in the mid-1900s, reacting natural castor oil with ethylene oxide, looking to transform its solubility and expand its use in the burgeoning pharmaceutical industry. That ingenuity turned a tried-and-true folk remedy into a technical workhorse for solubilizing active pharmaceutical ingredients that wouldn’t mix well with water. Over decades, tides of regulatory standards—British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP)—shaped and solidified how this ingredient shows up around the globe, both in paperwork and in factories.
Polyoxyethylene 35 Castor Oil (often called Cremophor EL, Kolliphor EL, or just POE 35 Castor Oil) isn’t just another synthetic chemical. It takes castor oil and grafts about 35 moles of ethylene oxide onto each molecule, unlocking the kind of solubility you just can’t coax out of plain vegetable oil. This puts it front and center in injectable formulations, emulsions, and eye drops. Plenty of big-name drugs you’d find on pharmacy shelves—think chemotherapy treatments—draw on its ability to blend oily molecules with water so patients absorb medicines properly and steadily.
A clear to slightly yellow viscous liquid, POE 35 Castor Oil carries a faint odor that’s hard to pin down. It dissolves easily in water and alcohol, but resists mixing with mineral oils or aromatic hydrocarbons. Viscosity sits comfortably high, usually in the range of 600-800 mPa·s at 25°C. The surface-active properties come from its long polyethylene oxide chains, which hug both water and oil, lowering surface tension. pH hovers around neutral. What catches the eye most is the high HLB value (typically 12–14), stamping its passport as an efficient water-soluble nonionic surfactant. Its cloud point—often above 60°C—sets practical limits for heat stability in sensitive formulations.
Regulators don’t mess around with their requirements. Each pharmacopoeia spells out clear tests for content of ethylene oxide, acidity, saponification value, water content, and microbial purity. For BP/EP/USP grades, heavy metal content can’t stray beyond a few parts per million. Residual ethylene oxide is tightly limited because of its toxicity. Any manufacturer shipping barrels of product needs airtight documentation on the lot’s specifications. Labels must note batch number, storage temperature (preferably below 25°C), gross and net weight, and expiry date. Tracking those details may not look exciting, but plenty of recalls and batch failures start with loose labeling.
Getting from castor bean to pharmaceutical-grade POE castor oil is a dance between raw plant oils and high-pressure chemistry. After extracting castor oil through pressing or solvent extraction, chemists react it with controlled amounts of ethylene oxide. This creates polyoxyethylene chains on almost every hydroxyl group the molecule has. Large reactors, often jacketed for temperature control, mix and pressurize the ingredients. Catalysts help manage reaction rates and chain lengths. Purification takes several rounds, including vacuum stripping, to pull out any unreacted ethylene oxide and byproducts. Quality checks often happen right alongside the production line, since even trace contaminants can derail safety.
Life as a surfactant relies on the length and uniformity of those polyoxyethylene chains. Chemists can tweak average chain length to alter HLB values, nudging the substance to suit specific applications—from injectable drugs to skin creams. Sometimes they're called on to functionalize the terminal groups, improving compatibility or stability for highly sensitive drugs. Under certain conditions, oxidation of the ethylene oxide groups may occur, resulting in unwanted aldehyde or carboxylate impurities, which labs must screen out. Glycosidic or ester modifications aren’t typical for pharmaceutical grades, but research labs explore all sorts of tweaks to anchor new benefits.
Drug firms, chemical suppliers, and even regulatory books don’t stick to one name. Polyoxyethylene 35 Castor Oil picks up synonyms like Macrogol Glycerol Ricinoleate, Cremophor EL, Kolliphor EL, or simply PEG 35 Castor Oil. Some catalogues list it under CAS 61791-12-6. “Tween 80” often shows up in related conversations, but that’s a different ethoxylated sorbitan ester. Whenever researchers or manufacturers compare studies and safety data, mixing up product names muddies the water and can block progress or proper hazard assessment.
Factories manufacturing POE castor oil stick to strict health and safety protocols. Operators wear gloves, goggles, and sometimes full respirators around concentrated ethylene oxide and during final blending. Environmental controls collect fugitive vapors and run them through scrubbers. Finished product storage happens in tightly sealed drums, away from direct sunlight or high heat, to avoid oxidation or hydrolysis. Pharmacopeial standards ensure finished batches test negative for bacteria, endotoxins, and potentially carcinogenic residuals. The broader medical field stays alert to patient reactions, especially since a minority experience hypersensitivity or even severe anaphylaxis after exposure to formulations containing POE castor oil.
As a solubilizer and emulsifier, POE 35 Castor Oil steers some of the toughest injectable and oral drugs into safe, stable forms. Paclitaxel—a core chemotherapy for breast and ovarian cancer—relies entirely on this excipient to make it water-soluble enough for IV delivery. Eye drops use it to suspend vitamins or deliver immunomodulators without streaking the lens or blurring vision. Soft gelatin capsules and topical creams turn to it for improved active ingredient dispersal. Even some veterinary and cosmetic products select pharmaceutical-grade material where purity can’t be compromised. Each application pivots off the same strengths: blending oils and waxes with water, holding medicines together through manufacturing, transport, and storage.
Drug development moves fast, but excipients like POE 35 Castor Oil often must keep pace with new demands for safety, stability, and reliability. Current research explores alternatives for patients at risk of severe allergic reactions, sometimes through subtle chemical changes to the polyethylene oxide length or source material. Scientists examine how the excipient interacts with new biological drugs, including mRNA and novel peptides. Analytical labs run long-term stability trials under tough conditions—freezers, humid warehouses, and truck transport—because regulatory authorities demand reliablility over years. Efforts to improve traceability and reduce potential byproducts steer manufacturers toward greener, safer production methods, improving yield while dropping known risks.
No pharmaceutical excipient escapes scrutiny, and POE castor oil is no different. Repeated clinical investigations and animal studies paint a complex picture. Most patients handle the ingredient just fine, but a notable share experience adverse reactions, mainly after IV administration. Reports ranging from minor skin rashes to potentially fatal anaphylaxis have forced product labeling changes and special patient monitoring, especially in cancer therapy. Animal studies indicate low acute toxicity, though chronic dosing can cause liver and kidney strain. Every batch must show minimal residual ethylene oxide and 1,4-dioxane, two byproducts that raise red flags for toxicity and carcinogenicity. Ongoing research looks for safer analogues to cut down the number of patients experiencing allergic or hypersensitive responses.
The worst-case scenario of reaction risk shadows every lot of POE 35 Castor Oil heading to a hospital pharmacy. New drug molecules on the way—particularly biologics and cell therapies—demand even tighter solubilizer profiles, pushing research teams to hunt for alternatives with fewer side effects. Green chemistry approaches hope to swap out ethylene oxide for safer epoxides from renewable sources. Some researchers are looking into using shorter PEG chains to reduce allergenicity without losing dispersing power. Further automation in manufacturing and stricter raw material traceability aim to prevent contamination before it happens. As patients continue to push for safe, effective treatments, innovation in excipient chemistry stays on the front burner, making sure that fixes for today’s formulation problems don’t set up tomorrow’s safety crisis.
Polyoxyethylene 35 castor oil, known in the pharma world as Kolliphor EL or Cremophor EL, comes from castor oil after getting mixed with ethylene oxide. The finished product turns into a thick, colorless, sticky liquid. At first glance, it hardly grabs much attention, but its job makes a difference in drug development and delivery.
Medications often deal with oily or fat-soluble ingredients. Many active drug molecules just don’t dissolve in water, and that causes a real headache because most injectable and oral medicines rely on water as their main partner. Polyoxyethylene 35 castor oil helps break down this separation between oil and water by acting as a surfactant. It lets oily medicines blend better with water, making sure the active ingredient travels smoothly through the bloodstream or digestive tract.
Anyone who takes medication for cancer, organ transplant, or other life-threatening diseases could run into this substance. Paclitaxel, a well-known cancer drug, uses polyoxyethylene 35 castor oil in its formula. Without it, that drug couldn’t reach cancer cells inside the body. Transplant medications, some anti-allergy injections, and vitamins for intravenous use often rely on this same ingredient.
Some people in hospitals may notice reactions when given drugs that use polyoxyethylene 35 castor oil. Allergic responses—wheezing, hives, or low blood pressure—sometimes pop up, especially with IV delivery. It doesn’t happen to everyone, but enough patients experience these problems that doctors stay cautious. I’ve spoken with nurses who triple-check cancer drug infusions, paying close attention to signs of intolerance. The unpredictability of these side effects means that premedication with steroids and antihistamines becomes routine. No one likes to add more drugs just to tolerate a treatment, but lives depend on it working right.
Animal studies and human case reports point to this surfactant as the cause behind some reactions, not always the drug itself. It’s a frustrating reality for both the patient and healthcare workers. Biopharma researchers see the same trend in preclinical safety tests, and the FDA collects reports about these side effects. Still, there’s no simple way around the need for a good solvent in many modern drugs.
Drugmakers keep searching for gentler alternatives. There’s ongoing research into other non-ionic surfactants, natural lipid-based carriers, and re-formulation tricks that make drugs more water-friendly right from the start. In the breast cancer world, new versions of paclitaxel use albumin particles, skipping polyoxyethylene 35 castor oil completely. Early data show that these newer options lower the risk of severe reactions and reduce preparation steps. Every advancement helps patients and staff breathe easier.
Anyone taking or prescribing medications can ask questions about what’s in the formulation, especially for injectables. Pharmacists remain valuable sources for this information, and open discussions about risks and benefits drive safer choices. No one should feel left in the dark about what goes into their body, and awareness keeps the entire system honest and improving. As regulators and scientists learn more, expect to see a wider range of options that work without so many side effects.
You’ll often spot Polyoxyethylene 35 Castor Oil, also called polysorbate 35 or Cremophor EL, on the ingredient lists for injectable drugs, vaccines, and some oral medications. Drug makers lean on it because it acts as a powerful emulsifier. It takes oil-based compounds that don’t otherwise mix with water and helps dissolve them into safe, clear solutions. That’s crucial for drugs that get delivered intravenously since any clumping or separation can cause dangerous reactions inside the body.
Hospitals and clinics routinely use medications that contain this compound. It’s regulated by authorities like the US FDA and the European Medicines Agency. That scrutiny isn’t just surface level—both demand solid evidence for safety before granting approval. Clinical studies dating back decades have tracked patient experiences, and, for the most part, folks tolerate doses in medications pretty well.
Still, nothing used in pharmaceuticals skips controversy. Some drugs that use this surfactant, such as the chemotherapy drug paclitaxel, have reported side effects linked to this ingredient. There have been rare but serious allergic-type reactions and difficulty breathing right after infusion starts. Allergic reactions do remind us that even long-accepted chemical agents can carry risk.
Few people realize that this compound is based on castor oil, which itself doesn’t raise many eyebrows. Only after scientists add the polyoxyethylene groups does it become the surfactant in question. The main worry—supported by case reports—is hypersensitivity, which isn’t that different from how people respond to food or other drug allergies.
Hospitals prepare for this possibility. Medical staff pre-treat patients with antihistamines or steroids for certain medications and ask about allergic history before administering these drugs. Major reviews suggest that most populations will never experience a reaction, but those with allergy-prone histories should be monitored closely.
Medical professionals track these rare incidents through pharmacovigilance programs. These systems collect reports, do follow-ups, and, if trends develop, regulators review the compound’s approval. After decades of extensive use, the overall rate of major side effects is quite low compared to the large numbers treated. Authorities like the FDA maintain that, as long as the compound is used as intended and monitored, the benefits outpace the risks.
No one can promise that an ingredient carries zero risk, but objective data matters. I’ve talked with pharmacists and nurses who have used medications containing Polyoxyethylene 35 Castor Oil on thousands of patients. Only a small fraction needed any extra intervention beyond routine monitoring. That kind of data goes beyond what’s possible in clinical trials and gives a pretty full picture of real-world safety.
Chemists stay on the hunt for alternatives, especially for the rare patients with sensitivity. Researchers have looked at new emulsifiers, lipid nanoparticles, and tweaks to drug formulations. The goal: avoid the need for this surfactant at all, especially for folks with a track record of allergies. Drug companies now list the full ingredient profile and include warning labels.
Practical solutions include asking about patient allergy history, flagging medications with known risk, and keeping resuscitation equipment on hand during infusions. Reporting every suspected side effect to national monitoring programs helps keep the data pool up to date and ensures safety guidance reflects the latest experience.
Pharmaceutical ingredients often don’t grab headlines, but ask anyone who develops, manufactures, or regulates medicines—they’ll tell you excipients like Polyoxyethylene 35 Castor Oil play an essential role in drug safety and performance. I’ve spent time in labs and around production lines, and I’ve seen how tight specifications matter. Patients rely on quality. Health agencies expect nothing less. QCs feel the daily pressure to make sure every drum meets the rules—no shrugged shoulders allowed for pharmaceuticals.
Polyoxyethylene 35 Castor Oil, often called PEG 35 Castor Oil or by the brand Cremophor EL, earns its place in pharmaceutical products by ticking the right boxes for the world’s main pharmacopeias: British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). Each reference book sets out a strict set of quality demands, often worded a little differently but aiming for the same targets—safety, purity, and performance in medicinal use.
Nobody wants surprises hidden in an excipient. Top-grade Polyoxyethylene 35 Castor Oil comes as a clear or slightly yellow, viscous liquid—almost odorless, and definitely tasteless. This stuff has to dissolve medicines without causing trouble. Standards demand a narrow pH, usually between pH 6.0 to 7.5—too acidic or too alkaline, and the batch won’t pass. Water content stays below 2.0%; otherwise, hydrolysis can kick off and mess with drug formulations.
History has taught us that harmful byproducts lurk in poorly purified ingredients. Each batch gets tested for acid value, usually under 2.0, since leftover acids signal incomplete processing. The saponification value has to hit the sweet spot, commonly ranging around 55–65, ensuring the right mixture of castor oil and polyoxyethylene chains. Residual ethylene oxide and dioxane get tracked closely—nobody wants to risk toxic contamination, and the allowed levels dip to extremely low parts per million.
I recall seeing how product gets rejected on the loading dock if it fails color, clarity, or odor checks—tiny details can put lives at risk down the line. The USP, EP, and BP requirements agree on this point. Foam test results must fall within strict ranges since excess foaming spells trouble in injectable or oral solutions. Unsaponifiable matter, often capped at 3%, catches any sneaky impurities from the original castor oil that stubbornly resist modification.
Batches must remain stable at room temperature, not break down, separate, or grow nasties like bacteria or fungi. Microbial testing forms a non-negotiable part of every release. Heavy metals, specially lead and arsenic, get checked with upper limits (often under 10 ppm for lead and 2 ppm for arsenic). Every parameter gets tracked, logged, and reviewed before those drums leave the plant.
Quality doesn’t stop at passing quarterly audits. I’ve seen problems come up when teams don’t monitor aging stocks or let polyoxyethylene content drift off-spec. Regular calibration, staff training, and transparent data sharing with suppliers solve most headaches. Everyone—from the lab tech to the warehouse manager—has to stay sharp, because weak links can bring a recall. Reliable suppliers invest in clean rooms, automated batch records, and third-party certification, which buys peace of mind.
Health regulators worldwide keep pushing standards higher. Digital batch tracing, rapid-release analytics, and eco-friendly purification are popping up in new production lines. Drug makers want longer shelf lives and less risk of allergic response, so excipient suppliers chase even lower toxicity benchmarks. These aren’t empty moves; they’re shaped by stories of past errors or supply chain lapses. It takes grit and vigilance to earn trust in pharma, and Polyoxyethylene 35 Castor Oil won’t escape scrutiny anytime soon.
Polyoxyethylene 35 Castor Oil shows up in a surprising number of products, from medical injections to cosmetics. Storing this ingredient the right way doesn’t just keep costs down — it keeps people safe. From what I’ve seen in pharmaceutical work, products like this one can break down if they sit in the wrong conditions. Once that happens, their performance changes, and so does their safety profile. There’s also a bigger picture: the Food and Drug Administration expects tight controls on ingredients for injectables, so careless storage can trigger recalls or disrupt the supply chain.
Keeping this oil in good shape starts with watching the temperature. Pharmacy shelves, chemical warehouses, and cosmetic labs all need to keep it cool, usually between 15°C and 30°C (roughly room temperature). But just meeting the numbers isn’t enough. Fluctuations invite trouble. Cold snaps can thicken the oil or create lumps. Heat speeds up chemical changes. In one lab I worked in, a shipment left near a drafty back door thickened so badly we had to toss half the lot.
Sealing makes a difference too. Moisture dips in every time someone pops a container open, especially on humid days, so drums and bottles must get sealed right after each use. Even small mistakes here draw in water. If the oil picks up extra moisture, it can cloud or separate. This turns it into a guessing game—no one wants to take bets with formulas that end up inside people’s bodies.
I’ve seen careless storage next to big warehouse windows. Sunlight breaks down all kinds of chemistries, and Polyoxyethylene 35 Castor Oil is no exception. Shaded spots or opaque bottles work better than glass jars under the sun. Original packaging almost always does the job, since it’s chosen for a reason. Once a batch gets poured into a new bottle, workers should label it right away and use it up soon, avoiding stockpiling small half-used containers.
People handling this ingredient can overlook the basics. Skin contact causes mild irritation for some, so gloves cut the risk. Spills feel sticky and drag shoes, but a quick mop and a soap wash clear them up. In a busy production room, slippery floors from spills have caused more near falls than any chemical reaction ever did. Eye protection guards against splashes, though I’ve seen experienced staff get careless around what they think of as “just oil." It only takes one slip or splash to rethink that.
Open drums and mix tanks can carry fumes. Good airflow is the best answer. Excessive fumes can build up in closed-off rooms, so I always ask about the ventilation before starting larger batches. Proper labeling on all containers is another habit I've found essential. Simple changes like bold, waterproof labels stop confusion and keep similar-looking liquids from getting switched.
Some leftover oil winds up needing disposal, especially from old, discolored, or contaminated stock. The best practice I picked up: Never pour it down drains. Local waste rules apply, but most labs collect used oil for professional disposal. In the event of a bigger spill, absorbent pads and sand do the job faster than rags alone. Used cleanup materials should get bagged up and labeled.
Keeping Polyoxyethylene 35 Castor Oil in good shape means treating it with as much respect as any active ingredient. Controlled temperatures, tight seals, and good habits in the storeroom or lab protect more than just the bottom line. They safeguard everyone down the chain, from workers to end-users.
Walk down the aisle of any pharmacy and you’ll find a lineup of medicines made possible by something as overlooked as Polyoxyethylene 35 Castor Oil—also known as Cremophor EL. It’s a clear, pale yellow liquid that helps get tricky drugs into forms our bodies can use. My time working in a small compounding pharmacy and talking with hospital pharmacists showed me how often this ingredient pops up behind the scenes.
One of the biggest roles for Polyoxyethylene 35 Castor Oil is in injectable medications, especially those carrying active drugs that don’t play nicely with water. The classic example, paclitaxel, treats cancer patients throughout the world thanks to this solubilizer. Paclitaxel on its own refuses to dissolve in water, so it gets mixed with Polyoxyethylene 35 Castor Oil to make a stable solution that can be given directly into a vein. This is no small achievement; water-insoluble drugs often don’t work in standard tablets or liquid formulas, so techniques like this expand the options for treating serious illnesses.
It isn’t just injectables. Polyoxyethylene 35 Castor Oil shows up in certain oral capsules. Some vitamins and immune suppressants, such as cyclosporine, depend on this excipient to ferry the active ingredient through the gut and into the bloodstream. Years ago, a family member relied on cyclosporine after an organ transplant, and knowing how critical stable absorption was gave me a direct appreciation for these background ingredients. Topical creams designed to treat skin conditions, such as fungal infections, also use this oil to break up greasy or waxy compounds, producing lotions that actually sink into the skin rather than sitting on the surface.
The pharmaceutical industry leans on Polyoxyethylene 35 Castor Oil mainly in the form of oral soft gelatin capsules, emulsions for intravenous or intramuscular injections, and oil-in-water topical creams and lotions. Dosage varies based on the drug’s requirements, but for intravenous emulsions, concentrations commonly range from 1% to about 5%. For oral solutions, the range can go higher—sometimes up to 10% or more, depending on how stubborn the active ingredient acts during mixing.
No discussion would be fair without touching on the safety aspect. Some people experience allergic reactions—mostly during cancer chemotherapy. The reactions can range from rash and itching to severe breathing problems. Medical teams usually pre-treat with steroids or antihistamines. For patients with a history of allergies, my experience taught me to check labels carefully and flag concerns with doctors. As the FDA and the European Medicines Agency point out in their guidance, it’s not just about efficacy, it’s about safety for a wide range of patients.
Research keeps looking for alternatives to Polyoxyethylene 35 Castor Oil, but for now, it stays in the toolkit because it solves problems other carriers just can’t touch. Improved screening for allergic responses and new combinations with other excipients may reduce the risks. By strengthening oversight during both development and long-term monitoring, the industry can give patients the right treatment without unexpected surprises.
Chengguan District, Lanzhou, Gansu, China
